The identification of a clear standard of care for patients with advanced clear-cell renal cell carcinoma following anti-PD-1 or anti-PD-L1 therapy warrants study as an unmet need. We aimed to investigate belzutifan plus lenvatinib versus cabozantinib in participants with clear-cell renal cell carcinoma previously treated with immune checkpoint inhibitors.
LITESPARK-011 is a phase 3, open-label, randomised, active-controlled study conducted 184 medical centres in 25 countries in Asia, Australia, Europe, North America, and South America. Participants were aged 18 years or older with advanced unresectable, locally advanced or metastatic stage IV clear-cell renal cell carcinoma, with disease progression following anti-PD-1 or anti-PD-L1 therapy with or without previous VEGFR-tyrosine-kinase inhibitors. Participants were randomly assigned (1:1) to receive 120 mg belzutifan plus 20 mg lenvatinib (belzutifan–lenvatinib) or 60 mg cabozantinib orally once daily until disease progression or unacceptable adverse events occurred. Randomisation was done using a web-based interactive response system (block size four) and stratified by International Metastatic Renal-Cell Carcinoma Database Consortium prognostic score (0 vs 1–2 vs 3–6), line of previous immunotherapy (adjuvant, neoadjuvant-adjuvant, or first-line vs second-line), and geographical region (North America vs western Europe vs rest of the world). The dual primary endpoints were progression-free survival by masked independent central review and overall survival, assessed in all randomly assigned participants. Safety was assessed in all randomly assigned participants who received least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT04586231, and has completed participant recruitment and is ongoing with treatment and follow-up.
Between March 5, 2021, and Sept 1, 2023, 955 individuals were screened for eligibility, 747 of whom were randomly assigned to belzutifan–lenvatinib (n=371) or cabozantinib (n=376). 565 (76%) participants were male and 182 (24%) were female; 651 (87%) were White (table 1). second interim analysis (data cutoff April 9, 2025; median follow-up 29·0 months [IQR 23·7–34·9]), progression-free survival was significantly longer in the belzutifan–lenvatinib group compared with the cabozantinib group (median 14·8 months [95% CI 11·2–16·6] vs 10·7 months [9·2–11·1]; hazard ratio [HR] 0·70 [95% CI 0·59–0·84]; one-sided p
Belzutifan–lenvatinib represents a novel and efficacious treatment option. Although overall survival was not significantly different between the groups, belzutifan–lenvatinib might be a new standard of care for patients with advanced clear-cell renal cell carcinoma with disease progression after previous anti-PD-1 or anti-PD-L1 therapy. The safety profile of belzutifan–lenvatinib was consistent with those of the individual drugs.
Merck Sharp & Dohme, a subsidiary of Merck & Co.
Adjuvant therapy with pazopanib after metastesectomy for met-ccRCC did not show a meaningful benefit. It seems that the current standard is for adjuvant pembro after metastesectomy within a year of nephrectomy.